Document is current
Any future updates will be listed below
-
Authors
Ozirmak Lermi, Nejla https://orcid.org/0000-0001-6820-1456
Molina Ayala, Max
Hernandez, Sharia https://orcid.org/0000-0002-7746-0860
Lu, Wei
Khan, Khaja
Serrano, Alejandra
Lubo, Idania https://orcid.org/0009-0002-0545-1444
Hamana, Leticia https://orcid.org/0000-0001-5952-320X
Tomczak, Katarzyna
Barnes, Sean
Dou, Jinzhuang
Liang, Qingnan
,
Alrawi, Ahmed N.
Arrechedera, Claudio A.
Ayers, Kimberly S.
Bedoya, Caludia A.
Burton, Elizabeth
Chon, Connie A.
Chu, Randy A.
Crosby, Shadarra D.
Do, Jonathan
Lima, Cibelle FP
Szu-Chin, Fu
Futreal, Andy
Garcia, Ana L.
Garica-Prieto, Celia
Gite, Swati
Gumbs, Curtis
Hargraves, Kristin J.
He, Meng
Horombe, Chacha
Ibarguen, Heladio P.
Jackson, Stacy
Jacob, Jeena J.
Khanduri, Isha
Kinyua, Walter K.
Knafl, Mark
Lang, Wenhua
Little, Latasha D.
Mallampati, Saradhi
Mendoza, Mary GT
Meric-Bernstam, Funda
Mohammad, Mohammad M.
Piubelli, Mario LM
Prabhakaran, Sabitha
Shaw, Kenna R.
Song, Xiaofei
Subramanya, Sandesh
Sun, Baohua
Virani, Shumaila
Wang, Wanlin
Woodman, Scott E.
Xu, Mingchu
Zhang, Jianhua
Zhang, Qingxiu C.
Zhang, Shanyu
Raso, Maria Gabriela https://orcid.org/0000-0003-2105-5556
Tang, Ximing
Jiang, Mei
Sanchez-Espiridion, Beatriz
Weissferdt, Annikka
Heymach, John https://orcid.org/0000-0001-9068-8942
Zhang, Jianjun https://orcid.org/0000-0001-7872-3477
Sepesi, Boris
Cascone, Tina https://orcid.org/0000-0003-3008-5407
Tsao, Anne https://orcid.org/0000-0003-0505-6639
Altan, Mehmet https://orcid.org/0000-0001-9229-156X
Mehran, Reza
Gibbons, Don https://orcid.org/0000-0003-2362-3094
Wistuba, Ignacio
Haymaker, Cara https://orcid.org/0000-0002-1317-9287
Chen, Ken https://orcid.org/0000-0003-4013-5279
Solis Soto, Luisa M. https://orcid.org/0000-0002-1253-630X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (U24CA224285, P30CA016672, P50CA070907)
- License Information
-
More Information
Article History
Received: 6 January 2025
Accepted: 13 August 2025
First Online: 26 September 2025
Competing interests
: C.H. declares research funding to institution from Sanofi, BTG, Iovance, Obsidian, KSQ, EMD Serono, Takeda, Genentech, BMS, Summit Therapeutics, Artidis, Immunogenesis and Novartis; scientific advisory board member of Briacell with stock options; personal fees from Regeneron outside the scope of the submitted work. L.M.S.S. declares research funding to institution from Theolytics, advisory role/consulting fees from BioNTech, travel support for participation in 10x Genomic Pathology Day event and participation in NanoString Roadshow event, both unrelated to this work. M.A. declares research funding to institution from Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol Myers Squibb, Eli Lilly, Adaptimmune, Shattuck Lab, Gilead, Verismo therapeutics, Lyell; scientific advisory board member of GlaxoSmithKline, Shattuck Lab, Bristol Myers Squibb, AstraZeneca, Insightec, Regeneron, Genprex; personal fees from AstraZeneca, Nektar Therapeutics, SITC; participation of safety review committee for Nanobiotix-MDA Alliance, Henlius outside the scope of the submitted work. J.Z. declares research funding from Johnson and Johnson, Helius, Merck, Novartis and Summit, honoraria and consulting fees from AstraZeneca, BeiGene, Catalyst, GenePlus, Helius, Innovent, Johnson and Johnson, Novartis, Takeda and Varian outside the submitted work. D.G. has served on scientific advisory committees for Sanofi, Menarini Ricerche, Onconova, and Eli Lilly, and has received research support from Takeda, NGM Biopharmaceuticals, Boehringer Ingelheim and AstraZeneca. T.C. has received over the past 24 months speaker fees/honoraria (including travel/meeting expenses) from ASCO Post, AstraZeneca, Bio Ascend, Bristol Myers Squibb, Clinical Care Options, IDEOlogy Health, Medical Educator Consortium, Medscape, OncLive, PEAK Medicals, PeerView, Physicians’ Education Resource, Targeted Oncology; advisory role/consulting fees (including travel/meeting expenses) from AstraZeneca, Bristol Myers Squibb, Genentech, Merck, oNKo-innate, Pfizer, and RAPT Therapeutics; institutional research funding from AstraZeneca and Bristol Myers Squibb. All other authors declare no competing interests.
